OncoMatch/Clinical Trials/NCT06648434
MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Is NCT06648434 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Zunsemetinib and mFOLFIRINOX for metastatic pancreatic ductal adenocarcinoma.
Treatment: Zunsemetinib · mFOLFIRINOX — The investigators hypothesize that MK2 inhibition may improve efficacy of mFOLFIRINOX chemotherapy for patients with pancreatic ductal adenocarcinoma (PDAC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage IV
Diagnosis of advanced inoperable or metastatic disease, where mFOLFIRINOX (or classical FOLFIRINOX) is deemed a suitable option per the treating physician. Measurable disease by RECIST 1.1.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Exception: Prior adjuvant/neoadjuvant therapy (including FOLFIRINOX or mFOLFIRINOX regimens) is allowed if progression occurred ≥ 12 months from the last dose of that therapy.
no prior systemic treatment for advanced or metastatic disease. Prior adjuvant/neoadjuvant therapy (including FOLFIRINOX or mFOLFIRINOX regimens) is allowed if progression occurred ≥ 12 months from the last dose of that therapy.
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5 K/cumm; Platelets ≥ 100 K/cumm without transfusion within 2 weeks prior to C1D1; Hemoglobin ≥ 9.0 g/dL without transfusion within 2 weeks prior to C1D1
Kidney function
Creatinine clearance > 50 mL/min by Cockcroft-Gault
Liver function
Total bilirubin ≤ 1.5 x IULN; AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN, unless there are liver metastases in which case AST and ALT ≤ 5.0 x IULN
Cardiac function
Baseline EKG with QTcF ≤ 460 ms
Adequate bone marrow and organ function as defined below: Absolute neutrophil count ≥ 1.5 K/cumm; Platelets ≥ 100 K/cumm without transfusion within 2 weeks prior to C1D1; Hemoglobin ≥ 9.0 g/dL without transfusion within 2 weeks prior to C1D1; Total bilirubin ≤ 1.5 x IULN; AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN, unless there are liver metastases in which case AST and ALT ≤ 5.0 x IULN; Creatinine clearance > 50 mL/min by Cockcroft-Gault; Baseline EKG with QTcF ≤ 460 ms.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington University School of Medicine · St Louis, Missouri
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06648434 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages